Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||acute myeloid leukemia||not applicable||Mivebresib + Venetoclax||Preclinical - Cell line xenograft||Actionable||In a preclinical study, Mivebresib (ABBV-075) and Venclexta (venetoclax) worked synergistically to decrease viability of a acute myeloid leukemia (AML) cell lines in culture, and the combination resulted in increased tumor growth inhibition in an AML cell line xenograft model compared to either agent alone (PMID: 28416490).||28416490|